[
  {
    "ts": null,
    "headline": "Moderna Announces Data to be Presented at the 2025 International Congress of Inborn Errors of Metabolism",
    "summary": "CAMBRIDGE, MA / ACCESS Newswire / September 2, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that five abstracts on its investigational mRNA therapeutics have been accepted for presentation at the 2025 International Congress of Inborn Errors ...",
    "url": "https://finnhub.io/api/news?id=83b68aed9b6d0d6716203560c8a4636154d698a7173cd36db37f2e823053e436",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756814400,
      "headline": "Moderna Announces Data to be Presented at the 2025 International Congress of Inborn Errors of Metabolism",
      "id": 136604684,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "CAMBRIDGE, MA / ACCESS Newswire / September 2, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that five abstracts on its investigational mRNA therapeutics have been accepted for presentation at the 2025 International Congress of Inborn Errors ...",
      "url": "https://finnhub.io/api/news?id=83b68aed9b6d0d6716203560c8a4636154d698a7173cd36db37f2e823053e436"
    }
  },
  {
    "ts": null,
    "headline": "Is Moderna Stock Underperforming the S&P 500?",
    "summary": "With Moderna heavily lagging behind the broader S&P 500 Index, Wall Street appears cautious about this stock.",
    "url": "https://finnhub.io/api/news?id=e6eec3e09cd26271831fd96cf69bd6177fe23518994d643046195320f5fe9345",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756807033,
      "headline": "Is Moderna Stock Underperforming the S&P 500?",
      "id": 136604685,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "With Moderna heavily lagging behind the broader S&P 500 Index, Wall Street appears cautious about this stock.",
      "url": "https://finnhub.io/api/news?id=e6eec3e09cd26271831fd96cf69bd6177fe23518994d643046195320f5fe9345"
    }
  },
  {
    "ts": null,
    "headline": "Moderna (MRNA) Gains FDA Nod for Next-Gen COVID-19 Vaccine Targeting LP.8.1 Variant",
    "summary": "Moderna, Inc. (NASDAQ:MRNA) ranks among the best mid-cap stocks with huge upside potential. Moderna, Inc. (NASDAQ:MRNA) reported on August 27 that the US Food and Drug Administration had granted supplementary Biologics License Applications for its 2025-2026 COVID-19 vaccination compositions aimed at the LP.8.1 variant of SARS-CoV-2. All adults 65 years of age and over, as […]",
    "url": "https://finnhub.io/api/news?id=29f725c91f470876a3261f4acaeb78cf68d7d265bfbf1c9257503614f0c51f2c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756794887,
      "headline": "Moderna (MRNA) Gains FDA Nod for Next-Gen COVID-19 Vaccine Targeting LP.8.1 Variant",
      "id": 136604686,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Moderna, Inc. (NASDAQ:MRNA) ranks among the best mid-cap stocks with huge upside potential. Moderna, Inc. (NASDAQ:MRNA) reported on August 27 that the US Food and Drug Administration had granted supplementary Biologics License Applications for its 2025-2026 COVID-19 vaccination compositions aimed at the LP.8.1 variant of SARS-CoV-2. All adults 65 years of age and over, as […]",
      "url": "https://finnhub.io/api/news?id=29f725c91f470876a3261f4acaeb78cf68d7d265bfbf1c9257503614f0c51f2c"
    }
  },
  {
    "ts": null,
    "headline": "3 Healthcare Stocks with Warning Signs",
    "summary": "From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand. The result? Over the past six months, the industry’s return was flat while the S&P 500 climbed by 10.5%.",
    "url": "https://finnhub.io/api/news?id=43ed6bd58ebc848f8ece5aa293bac619207ea3bceb0e36d3568efdaf1172ecc9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756791238,
      "headline": "3 Healthcare Stocks with Warning Signs",
      "id": 136604687,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand. The result? Over the past six months, the industry’s return was flat while the S&P 500 climbed by 10.5%.",
      "url": "https://finnhub.io/api/news?id=43ed6bd58ebc848f8ece5aa293bac619207ea3bceb0e36d3568efdaf1172ecc9"
    }
  }
]